Previous 10 | Next 10 |
Gainers: Nxt-ID (NXTD) +50%.Diginex (EQOS) +48%.Aethlon Medical (AEMD) +40%.MIND Technology (MIND) +27%.Aclaris Therapeutics (ACRS) +24%.Tilray (TLRY) +23%.MiMedx Group (MDXG) +22%.Amyris (AMRS) +21%.Drive Shack (DS) +20%.Marathon Patent Group (MARA) +19%.Losers: Concord Medical Services...
Palm Beach, FL – December 15, 2020 – While the pharmaceutical industry has had an amazing record of developing therapeutic drugs for countless uses, sometimes, a remaining part of the problem is how do you get the drug into the patient’s body? The simplest way is usuall...
In addition to positive topline data from early-stage atopic dermatitis study with EDP1815 announced earlier today, Evelo Biosciences ([[EVLO]] +12.2%) has announced that it is prioritizing EDP1908 as its lead clinical candidate in oncology given its superior preclinical a...
–EDP1908 announced as clinical candidate in oncology after showing superior preclinical activity over EDP1503– –Interim clinical data for EDP1503 suggest potential of orally delivered SINTAX™ product candidates to activate systemic immunity– CAMBRIDG...
Intec Pharma (NTEC) +111% after research pact with UK-based GW Pharma.Recon Technology (RCON) +102%.Francesca's Holdings (FRAN) +99% after receiving court approval of first day motions to support ongoing operations.ZW Data Action Technologies (CNET) +101% after opening its firs...
Evelo Biosciences (EVLO) jumps 15% premarket on positive topline data from its Phase 1b clinical trial of EDP1815 in 23 evaluable subjects with mild to moderate atopic dermatitis.The primary endpoint was safety and tolerability. EDP1815 was well tolerated with no serious adverse eve...
– Treatment with EDP1815 demonstrates statistically and clinically significant improvement in mean EASI and IGA* BSA scores – – EDP1815 first-ever candidate targeting SINTAX ™ to show clinical activity in Th1, Th2, ...
Evelo Biosciences (EVLO) has achieved enrollment necessary for the interim data readout in the Phase 2 EDP1815-201 trial evaluating EDP1815 for the treatment of mild to moderate psoriasis.The interim data readout will include initial safety and efficacy data for the first ...
CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in the small intestine with systemic effects, today announced that it is recruiting ahead of s...
Evelo Biosciences seeks to harass the ability of microbes in the gut to direct the immune system. The approach is novel and unproven and thus investing is a very high risk proposition. If efficacious, these are benign, inexpensive to manufacture products which can provide treatmen...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...